A study of the clinical and epidemiological characteristics of patients with systemic sclerosis at a single center in Baghdad | [Journal of Pakistan Association of Dermatologists • 2024]

Author(s):

1. Douaa Aziz Darfash: College of Health & Medical Techniques-Baghdad, Middle Technical University,Baghdad,Iraq

2. Ishraq Ahmed Chiad: College of Health & Medical Techniques-Baghdad, Middle Technical University,Baghdad,Iraq

3. Ali Hussein Al Hafidh: College of Health & Medical Techniques-Baghdad, Middle Technical University,Baghdad,Iraq

Abstract:

Background In patients with systemic sclerosis, a chronic autoimmune illness, the immune system becomes dysregulated, blood vessels are damaged, and organs and skin become fibrotic. Biomarkers are essential in clinical practice because they allow for accurate diagnosis, the prediction of disease development, and the assessment of the effectiveness of treatment. The aim of the study is to determine the variety aspects of clinical and epidemiological factors of Iraqis' systemic sclerosis. Methods A cohort of 39 individuals diagnosed with Systemic Sclerosis (SSc) were involved in the current cross-sectional investigation. The research was carried out from December 15, 2022, to May 30, 2023, utilizing a specifically crafted questionnaire. Results Overall, 100% of the people who took part had thicker skin. Following this were Raynaud's phenomenon (97.5%), abnormal nail fold capillaries (94.9%), telangiectasia (85.8%), oral puckering, dysphagia, and puffy fingers (79.5%), and finally shortness of breath and sclerodactyly (77%). Additionally, 73.8% of participants had ILD, and 19.0% had pulmonary hypertension. ANA positivity was seen in 90% of the patients. There is a strong association between the presence of anti-Sc1-70 antibodies and DcSSc. In the limited form, only one case (2.56%) tested positive, while 23 cases (58.97%) tested positive. This association was shown to be statistically significant with a p-value < 0.001. Patients with limited cutaneous systemic sclerosis (LcSSc) were much more likely than those with diffuse cutaneous systemic sclerosis (DcSSc) to have anti-centromere antibodies (ACA), with rates of 17.95% for LcSSc and 10.25% for DcSSc (p = 0.037). Conclusion SSc has a higher frequency among the female population. Typically, the first clinical manifestation is Raynaud's phenomenon, but other symptoms may manifest at any stage of the disease's unpredictable course.

Page(s): 630-638

DOI: DOI not available

Published: Journal: Journal of Pakistan Association of Dermatologists, Volume: 34, Issue: 3, Year: 2024

Keywords:

Systemic sclerosis , Interstitial lung disease , Diffuse systemic sclerosis

References:

[1] Sobolewski P,Maślińska M,Wieczorek M,Łagun Z,Malewska A,Roszkiewicz M .2019 .Systemic sclerosis- multidisciplinary disease: clinical features and treatment. Reumatologia, 57 : 221-33.

[2] Van Den Hoogen F,Khanna D,Fransen J,Johnson SR,Baron M,Tyndall A .2013 .classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum, 65 : 2737-47.

[3] Senécal JL,Hoa S,Yang R,Koenig M. .2020 .Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis. J Scleroderma Relat Disord, 5(2) : 103-29.

[4] Nihtyanova SI,Denton CP .2010 .Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol, 6 : 112-6.

[5] LeRoy EC,Black C,Fleischmajer R,Jablonska S,Krieg T,Medsger TA .1988 .Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol, 15 : 202-5.

[6] Walker UA,Tyndall A,Czirják L,Denton C,Farge-Bancel D,Kowal-Bielecka O .2007 .Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials. Ann Rheum Dis, 66 : 754-63.

[7] Calderon LM,Pope JE .2021 .Scleroderma epidemiology update. Curr Opin Rheumatol, 33 : 122-7.

[8] Bairkdar M,Rossides M,Westerlind H,Hesselstrand R,Arkema EV,Holmqvist M. Incidence .2021 .and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford), 60 : 3121-33.

[9] Ruaro B,Sulli A,Pizzorni C,Paolino S,Smith V,Cutolo M. .2016 .Correlations between skin blood perfusion values and nailfold capillaroscopy scores in systemic sclerosis patients. Microvasc Res, 105 : 119-24.

[10] Elbraky F,Amailaf I,Alsaeiti K. .2020 .Demographic characteristics and clinical manifestations of systemic sclerosis in Benghazi, Libya. Ibnosina Journal of Medicine and Biomedical Sciences, 12 : 118-22.

[11] Asif S,Khan A,Faiq M,Din ZU,Zahoor S,Haroon M. .2021 .Clinical and serological characteristics of systemic sclerosis: Experience of a tertiary care center in Pakistan. Arch Rheumatol, 36 : 587-94.

[12] Arif T,Adil M,Sodhi JS .2019 .Upper gastrointestinal endoscopy in systemic sclerosis: A cross sectional study. J Pak Assoc Dermatol, 29(4) : 374-83.

[13] Alam F,Abdulaziz HM,Ul Haq I,Mahdy SM,Mohammed Siam AR,Chandra P .2019 .Characteristics of patients with systemic sclerosis living in Qatar. Qatar Med, : 16.

[14] Li H,Zhang X,Yu L,Shang J,Fan J,Feng X .2022 .Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center. Front Med (Lausanne), 10 : PMC9763297.

[15] Jawad ZY,Gorial FI .2017 .Ocular manifestations of systemic sclerosis: A descriptive cross sectional study from Iraq. IOSR Journal of Nursing and Health Science, 06 : 94-7.

[16] Gorial FI,Swady RN .2018 .Prevalence of depression in Iraqi patients with systemic sclerosis and its relationship with disease severity. Int J Med Res Health Sci, 7 : 69-74.

[17] Antinozzi C,Grazioli E,De Santis M,Motta F,Sgrò P,Mari F .2022 .The preventive role of physical activity in systemic sclerosis: A cross-sectional study on the correlation with clinical parameters and disease progression. Int J Environ Res Public Health, 10(16) : 10303.

[18] Çevik R,Em S,Nas K,Toprak M,Cengiz G,Çalış M .2023 .Association of pain and clinical factors on disability and quality of life in systemic sclerosis: A cross-sectional study from Turkish League Against Rheumatism Network. Arch Rheumatol, 38 : 9-21.

[19] Silva AM,Roque LCSC,Gonçalves RSG,Duarte ALBP,Tenório A da S,Dantas AT .2020 .Evaluation of quality of life, functionality and disability in patients with systemic sclerosis in a University Hospital. , 45 : e020025.

[20] Rajaei E,Hessam A,Mowla K,Zayeri ZD .2019 .Statistical analysis of clinical and laboratory characteristics of systemic sclerosis. Tehran Univ Med J, 77(9) : 568-71.

[21] El-Safty A,Yossef Manal,Abdul-Sattar A .2020 .Characteristics of systemic sclerosis patients in Zagazig University Hospitals; A cross sectional study. , 29 : 44-52.

[22] Żebryk P,Przymuszała P,Nowak JK,Piorunek T,Mularek-Kubzdela T,Puszczewicz M. .2023 .Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study. J Clin Med, 12(2) : 657.

[23] Namas R,Elarabi M,Khan S,Mubashir A,Memisoglu E,El-Kaissi M .2023 .Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry. J Scleroderma Relat Disord, 8(2) : 137-150.

[24] Alian SM,Sherby NA,Sarhan SA .2021 .Cultural adaptation and validation of the Systemic Sclerosis Quality of Life questionnaire into Arabic language. Clin Rheumatol, 40 : 1409-16.

[25] Ghosh S,Tanna D,Telang K,Dhuria S,Gupta R. .2023 .Clinical and autoantibody profiles of systemic sclerosis patients: A crosssectional study from North India. Indian J Dermatol Venereol Leprol, : 1-7.

[26] Heyne S,Haufe E,Beissert S,Schmitt J,Günther C .2023 .Determinants of Depressive Symptoms, Quality of Life, Subjective Health Status and Physical Limitation in Patients with Systemic Sclerosis. Acta Derm Venereol, 103 : adv6502.

[27] Tahiat A,Allam I,Abdessemed A,Mellal Y,Nebbab R,Ladjouze-Rezig A .2020 .Autoantibody profile in a cohort of Algerian patients with systemic sclerosis. Annales de Biologie Clinique, 78 : 126-33.

[28] Ng SA,Low AHL . .February 2022. , 10 : .

[29] Ghosh S,Tanna D,Telang K,Dhuria S,Gupta R. .2023 .Clinical and autoantibody profiles of systemic sclerosis patients: A crosssectional study from North India. Indian J Dermatol Venereol Leprol, : 1-7.

[30] Freitas R,Martins P,Dourado E,Santiago T,Guimarães F,Fernandes BM .2022 .Clinical features and outcome of 1054 patients with Systemic Sclerosis: analysis of Reuma.pt/SSc registry. ARP Rheumatol, 1(1) : 21-9.

[31] Mahler M,Hudson M,Bentow C,Roup F,Beretta L,Pilar Simeón C .2020 .Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev, 19 : 102583.

[32] Cottin V,Brown KK .2019 .Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res, 20 : 1-10.

[33] Stochmal A,Czuwara J,Trojanowska M,Rudnicka L M .2020 .Antinuclear Antibodies in Systemic Sclerosis: an Update. Clin Rev Allergy Immunol, 58 : 40-51.

[34] Ouazahrou K,El Bakkouri J,Souali M,Jeddane L,Mokhantar K,Errami A .2023 .7(2):rkad036. Rheumatol Adv Pract, 10 : .

[35] Krzyszczak ME,Li Y,Ross SJ,Ceribelli A,Chan EK,Bubb MR .2011 .Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol, 30 : 1333-9.

Citations

Downloads

Views